Liquid biopsy: A promising tool for driving strategies and predicting failures in patients with classic Hodgkin lymphoma.
Francesco PepeClaudia GiordanoGianluca RussoLucia PalumboAnnamaria VincenziGennaro AcanforaDario LisiMarco PicardiFabrizio PaneGiancarlo TronconeElena VigliarPublished in: Cytopathology : official journal of the British Society for Clinical Cytology (2023)
Classic Hodgkin lymphoma (cHL) consists of a heterogeneous group of haematological disorders that covers undifferentiated B cell neoplasms originating from germinal centre B cells. The HL molecular characterization still represents an ongoing challenge due to the low fraction of tumour Hodgkin and Reed-Sternberg cells mixed with a plethora of non-tumour haematological cells. In this scenario, next generation sequencing of liquid biopsy samples is emerging as a useful tool in HL patients' management. In this review, we aimed to overview the clinical and methodological topics regarding the implementation of molecular analysis in cHL, focusing on the role of liquid biopsy in diagnosis, follow-up, and response prediction.
Keyphrases
- hodgkin lymphoma
- induced apoptosis
- cell cycle arrest
- ultrasound guided
- end stage renal disease
- ionic liquid
- healthcare
- fine needle aspiration
- primary care
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- cell death
- endoplasmic reticulum stress
- prognostic factors
- chronic kidney disease
- dna methylation
- patient reported
- pi k akt